Category: Cardica Inc.
Cardica shares plunge after it suspends the launch of its MicroCutter Xchange 30 surgical stapler so it can focus on improving the product, a move that may also result in a realignment of its operations.
California surgical devices maker Cardica details a public offering of common and preferred stock aimed at raising $43.9 million to support U.S. sales and marketing efforts.
Cardica unveiled the details of an upcoming public offering of stock, aimed at raising $43.9 million to support commercial efforts for the company's MicroCutter XCHANGE 30 minimally invasive stapling system.
Cardica files for 510(k) clearance from the FDA for its MicroCutter Xchange 30 surgical stapling and cutting device.
Redwood City, Calif.-based Cardica (NSDQ:CRDC) said it filed for 510(k) clearance from the FDA for its surgical device.
Cardica and distribution partner Century Medical submit an application to Japanese regulators for Cardica's MicroCutter Xchange 30 cutting and stapling cartridges.
Cardica (NSDQ:CRDC) and its distribution partner Century Medical are shooting for Japanese regulatory approval for the stapling cartridge components of Cardica's MicroCutter Xchange surgical device.
During its 4th quarter Cardica tacked an additional $300,000 in losses to its bottom line, but managed to beat per-share earnings expectations by 1 cent.
Cardica (NSDQ:CRDC) fell further into the red with a 7% increase in 4th quarter losses compared to the same time last year, as well as an almost 20% increase in losses for the full year.
Novadaq says its deal with wound care giant Kinetic Concepts Inc. for the Luna wound imaging device the companies co-developed has come to an amicable end.
Novadaq Technologies (TSE:NDQ) said it and wound care giant Kinetic Concepts agreed to an amicable end to the co-development deal they inked in 2011 for the Luna wound imaging device.
Ocular Therapeutix raises another $24 million for its punctum plugs to treat eye diseases such as glaucoma.
Ocular Therapeutix said it closed a $23.8 million Series D extension round from existing backers for its sustained drug release technology to treat eye diseases.
The Bedford, Mass.-based medical device company said all of its current institutional investors ponied up for the round, including Polaris Ventures, Versant Ventures, SV Life Sciences, Sparta LLC, and Ascension Health Ventures.
Ocular Therapeutix is developing a punctum plug for the entry of the tear duct to release drug therapy to the surface of the eye over several months.